Optimal dose-fractionation schedule of palliative radiotherapy for patients with bone metastases: a protocol for systematic review and network meta-analysis

Xiaofang Tang, Qiancheng Hu, Ye Chen, Xin Wang, Xiaofen Li, Ke Cheng, Dan Cao

ABSTRACT

Introduction The optimal dose-fractionation schedule of palliative radiotherapy has been debated in patients with bone metastases. Our objective is to comprehensively compare multiple fraction schedules with single fraction radiotherapy in terms of efficacy and toxicities by performing a systematic review and network meta-analysis.

Methods and analysis Electronic searches of titles/abstracts of palliative radiotherapy for bone metastases will be performed, using PubMed, Cochrane Library, Embase, clinical trials, American Society for Therapeutic Radiology and Oncology and European Society of Radiotherapy and Oncology. The primary outcome of interest is the incidence of skeletal-related event following palliative radiotherapy for bone metastases in prospective studies. The risk of bias and quality of evidence will be evaluated based on Cochrane Collaboration’s tool and Grades of Recommendation, Assessment, Development and Evaluation in the network meta-analysis. We will conduct subgroup analysis and sensitivity analysis regardless of heterogeneity estimates.

Ethics and dissemination This study will synthesise the evidence regarding dose-fractionation schedule of palliative radiotherapy in patients with bone metastases. We hope the findings from this study will help clinicians and patients select optimum palliative radiotherapy by identifying the optimal dose-fractionation schedule of palliative radiotherapy with the most value in terms of patient-important outcomes. The evidence obtained from network meta-analysis will help to guide head-to-head research in the future. The results will be disseminated through international conference reports and peer-reviewed manuscripts. Ethics review board is not required for this network meta-analysis.

PROSPERO registration number CRD42019135195.

INTRODUCTION

Bone is the most frequent localisation where some tumours frequently develop secondary growth, with the incidence of over 85% patients with lung, breast or prostate cancers. Generally, bone metastases are asymptomatic in some cases, but it has been confirmed that at least 75% of patients with cancer presenting symptomatic bone metastases. Bone metastases induced skeletal-related events, for instance, pathological fractures, spinal cord compression and hypercalcaemia, impair quality of life and require multidisciplinary treatments.

Palliative radiotherapy could have considerable impact on patients with asymptomatic and symptomatic bone metastases. Palliative radiotherapy induced ossification is the key to successfully relieve cancer pain and kills tumour cells. In routine practice, five dose-fractionation schedules of radiotherapy, including 40 Gy (2Gy/fraction), 37.5 Gy (2.5 Gy/fraction), 30 Gy (3 Gy/fraction), 20 Gy (4 Gy/fraction) and 8 Gy (single fraction), are indicated for the treatment
of asymptomatic and symptomatic bone metastases; however, the optimal dose-fractionation scheme is a long-lasting controversy with the paucity of evidence to make the best choice for each patient.9

Ratanatharathorn et al found that higher dose fractionated radiotherapy produced better outcomes in pain control, in terms of frequency, duration and magnitude, than low-dose regimens.10 However, the majority of meta-analyses produced the opposite results suggesting that the differences between single fraction and multiple fraction radiation treatment regimens were small and non-significant.11–16

There is little incentive for researchers to conduct active comparison trials for dose-fractionation schedule of palliative radiotherapy, due in part to the cost of clinical trials. Therefore, it is useful to synthesise evidence available from existing trials in dose-fractionation schedule of available palliative radiotherapy to compare the direct (based on previous trial comparisons) and indirect effects (palliative radiotherapy which are not previously identified in head-to-head comparisons).17–19 Our objective is to evaluate the evidence of the role of palliative radiotherapy for patients with bone metastases and, using a network meta-analysis, comprehensively compare all multiple fraction schedules with single fraction radiotherapy in terms of efficacy and toxicities.

METHODS AND DESIGN

The protocol of network meta-analysis will be prepared according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA).20 We will report this system review and network meta-analysis according to the PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-Analyses of Health Care Interventions.21

Search strategy

Electronic searches by titles/abstracts of palliative radiotherapy for bone metastases will be performed, using PubMed, Cochrane Library, Embase (Ovid interface) and clinical trials (www.clinicaltrials.gov/). Titles and abstracts referring to palliative radiotherapy for bone metastases will be searched in the electronic American Society for Therapeutic Radiology and Oncology and European Society of Radiotherapy and Oncology. A time frame from conception to 18 April 2019 will be applied for the database search. Two authors who are experienced in the information retrieval will conduct separate search strategies independently. We will manually search references of included related systematic reviews/meta-analyses and other relevant publications to identify additional potential studies. We will record the reason for excluding the full text and generate a PRISMA flow diagram for the network meta-analysis.22

The search terms will include the following domains of Medical Subject Heading (MeSH) terms: ‘bone and bones’, ‘neoplasm metastasis’ and ‘radiotherapy’, according to Population Intervention Comparison Outcomes Study Design statement. MeSH and subheadings will be combined with ‘AND’ or ‘OR’. A sample PubMed search strategy is described in details in (see online supplementary appendix).

W e will perform a pilot test to evaluate inter-rater reliability and adjust each screening stage: title and abstract, followed by full-text screening. Independent reviewers will screen the titles/abstracts of related studies based on an inclusion and exclusion criteria. The eligible or potentially eligible trials will be assessed by reading through the full texts when necessary. Moreover, disagreements will be resolved by having a discussion, with the help of the third reviewer.

Eligibility criteria

The eligibility criteria must include the followings: (1) Symptomatic and asymptomatic bone metastases; (2) Interventions and Comparators: any dose-fractionation schedule of palliative radiotherapy, which is defined as alleviating focal symptoms of bone metastases or minimising the occurrence of skeletal related events with low total dose23 24; (3) Randomised controlled trials (RCTs) and prospective studies; (4) Report or provide enough information to calculate ORs; (5) The outcomes are overall response of pain and the incidence of skeletal related event (pathological fracture, spinal cord compression, surgery to bone and hypercalcaemia) and grades 3–4 haematological and non-haematological toxicity; (6) There will be no restriction on language, status and year of publication and (7) The samples are not subject to any restriction, for example, age, gender, performance status, ethnicity or nationality. The excluding criteria are applied as follows: (1) reirradiation, brachytherapy, radiopharmaceuticals, particle irradiation, intraoperative irradiation, half-body irradiation or concurrent irradiation and chemotherapy; (2) Reviews, posters, abstracts, editorials and case reports and (3) cross-sectional, cohort, case-control or retrospective study designs.

Outcomes

The primary outcome of interest is overall response of pain and the incidence of skeletal related event (pathological fracture, spinal cord compression, surgery to bone and hypercalcaemia)25 26 following palliative radiotherapy for bone metastases in prospective studies. Overall response of pain is defined as the sum of partial response and complete response. Pain progression is defined as at least a two-point increase in pain scores without a reduction in analgesics, or a ≥25% increase in analgesics without a decrease in pain scores. The partial response is defined as at least a two-point reduction in pain scores without an increase in analgesics, or an analgesic intake decreased by more than 25% without an increase in pain scores. The complete response is defined as a pain score of zero (no pain) and no increasing morphine equivalent dose daily. Indeterminate response is defined as response
that could not be classified according to pain progression, partial response or complete response definitions. The secondary outcomes are grades 3–4 haematological and non-haematological toxicity. The haematological toxicity is defined as anaemia, thrombocytopenia, leucopenia and neutropenia. For the response rates which are not reported in some trials, the percentages of responses will be recalculated according to the number of patients in the original studies.

Data extraction and management

The management of literature search records will be carried out in EndNote X7. A spreadsheet will be created in Microsoft Excel 2010 (Microsoft, Redmond, Washington, USA, www.microsoft.com) to collect outcomes of interest, such as the first author, study design, recruitment time frame, characteristics of bone metastases, details of interventions, sample size and endpoints (pain response, odds ratios and grades 3–4 haematological and non-haematological toxicity).

Bias risk

The quality and the risk of bias of RCTs will be estimated according to the following domains outlined in the Cochrane Collaboration’s tool, which includes seven specific domains: random sequence generation, allocation concealment, blinding of participants and personnel, incomplete outcome data, selective outcome reporting, and other bias. RCTs will be independently reviewed by two authors and reported as high risk of bias ‘+’, low risk of bias ‘–’, or unclear risk of bias ‘?’.

Quality of evidence

The quality of evidence in the network meta-analysis will be determined according to the five domains: risk of bias, imprecision, inconsistency, indirectness and publication bias. The staging system categorises GRADE evidence into four stages: (1) high, (2) moderate, (3) low and (4) very low quality. For RCTs, the starting confidence level for each network estimate is high, but will be rated down based on the evaluation of the five domains. For observational studies, the starting confidence level for each network estimate is low, but will be rated up based on the evaluation of the three domains: large effect, plausible confounding and dose–response gradient. We will complete the GRADE process with GRADE profiler software (GRADEpro V.3.6.1) (available at: www.gradeworkinggroup.org).

Direct comparison and network meta-analyses

We will perform the traditional pairwise meta-analysis between each direct comparison, and generate graphics (network map, contribution plot, comparisons adjusted funnel plot, pairwise meta-analysis, estimation of inconsistency, local heterogeneity and surface under the cumulative ranking curve (SUCRA graphs)) for network meta-analysis using Stata V.13.0 (StataCorp). A network plot will be constructed consisting of nodes and edges per outcome, and the weight of each node will be proportional to the number of patients. A contribution plot will be proposed to evaluate the contribution of direct and mixed interventions to the estimation of network meta-analytical summary effects. A comparison-adjusted funnel plot will be conducted to assess the potential publication bias of all included studies (if more than 10 studies are present). To compare all dose-fractionation schedule of palliative radiotherapy, network meta-analysis for all outcomes is planned using GeMTC V.1.4.3, (MRC Biostatistics Unit, Cambridge, UK). Results regarding the pain, skeletal related event, grades 3–4 haematological and non-haematological toxicity are expressed as ORs for dichotomous outcomes with 95% CIs/credible intervals. Both fixed and random-effects models will be run for pain, skeletal-related event, grades 3–4 haematological and non-haematological toxicity.

Transitivity, homogeneity and consistency assumption

To achieve valid results, we will perform three key assumptions underlying the network meta-analysis (transitivity, homogeneity and consistency assumption). First, we will conduct a thorough comparison of important study and patient characteristics. Second, we will perform a multivariate metaregression analysis to examine possible sources of heterogeneity using the same interventions. Lastly, indirect evidence via a common comparator is not different from direct evidence in the network.
Subgroup and sensitivity analyses
We will conduct prespecified subgroup analyses for our primary outcomes based on symptomatic and asymptomatic bone metastases. Symptomatic bone metastases are loosely defined as the use of palliative radiotherapy or surgical intervention to relieve pain, incident of new symptomatic pathological bone fractures and spinal cord compression, whereas asymptomatic bone metastases are defined as no bone pain and no evidence of pathological fracture or spinal cord compression. Additional subgroup analyses will be conducted, if possible, based on the cancer type (breast and prostate cancer vs others), site of bone metastases (vertebral metastasis vs limb metastasis) and publication year (before 2002 vs after 2002).

A series of three sensitivity analyses will be conducted according to the impact of Bayesian model (fixed-effect model vs random-effect model), study design (RCTs vs prospective studies) and overall low risk of bias. Then, additional sensitivity analyses will be conducted by excluding one paper at a time and observing the robustness of the results.

DISCUSSION
The high prevalence of bone metastases imposes a substantial socioeconomic burden, which attracts the attention of governments, pharmaceutical companies, academic researchers and other healthcare payers. More recent RCTs and non-RCTs have demonstrated the potential benefits of certain dose fractionations of palliative radiotherapy. However, the results of publications focusing on palliative radiotherapy in patients with bone metastases varied significantly for study designs and varying outcomes of interest, especially for different dose-fractionation schedule. The optimal dose-fractionation schedule of palliative radiotherapy in patients with bone metastases has long been debated, with multiple fraction schedules and single fraction radiotherapy in terms of efficacy, safety and cost-effectiveness. Accordingly, there are substantial practice changes among radiation oncologists treating bone metastases. Single fraction radiation remains frequently used in Europe, Canada and Australia, while multiple fraction radiation is likely advocated in the USA and China.

To the best of our knowledge, the results of network meta-analysis of prospective trials will fill a crucial knowledge gap of optimal dose-fractionation schedule of palliative radiotherapy in patients with bone metastases. We hope the findings from this study will help clinicians and patients select optimum palliative radiotherapy in the future by identifying the optimal dose-fractionation schedule of palliative radiotherapy with the most value in terms of patient-important outcomes. Additionally, currently under-recognised palliative radiotherapy comparisons may be identified by system reviews and network meta-analysis to guide future research and head-to-head RCTs.

Acknowledgements Thanks to Sun Feng and Wu Shanshan (PhD, Perking University School of public Health) for providing assistance and contributing to statistical analysis. (https://class.dky.cn/)

Contributors QH and DC conceptualised the network meta-analysis. QH and JW codedveloped the search strategy. Both XT and QH were major contributors in writing the manuscript. The protocol was revised by DC,YC, XL and KC. DC was serving as guarantor and corresponding author of this study. All authors approved the final manuscript and agreed to submit the protocol in the journal.

Funding The network meta-analysis was supported by the National Natural Science Foundation of China (grant no. 81773097).

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Dan Cao http://orcid.org/0000-0002-6709-4932

REFERENCES
1 Maroni P. Megakaryocytes in bone metastasis: protection or progression? Cells 2019;8:134.
2 Friedman SA, Radie-Keane K. The role of radiation therapy in the management of bone metastases. Med Health R I 1996;79:135–8.
3 De Felice F, Piccioli A, Musio D, et al. The role of radiation therapy in bone metastases management. Oncotarget 2017;8:25691–9.
4 Wagner G. Frequency of pain in patients with cancer. Recent Results Cancer Res 1984;95:64–71.
5 Aielli F, Ponzetti M, Rucci N. Bone metastasis pain, from the bedside. Int J Mol Sci 2019;20:280.
6 Wu JS-Y, Wong R, Johnston M, et al. Meta-Analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003;55:594–605.
7 Wu JS-Y, Wong RKS, Lloyd NS, et al. Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases - an evidence-based practice guideline. BMC Cancer 2004;4:71.
8 Gobbrisch MJ, Zwolak PP, Clohisy DR. Biology of bone cancer pain. Clin Cancer Res 2008;14:2914–5.
9 Rades D, Stalpers LJA, Veninga T, et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol 2005;23:3366–75.
10 Ratnamatharamon V, Powers WE, Moss WT, et al. Bone metastasis: review and critical analysis of random allocation trials of local field treatment. Int J Radiat Oncol Biol Phys 1999;44:1–18.
11 Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 2007;25:1423–36.
12 Chow E, Zeng L, Salvo N, et al. Update on the systematic review of palliative radiation therapy trials for bone metastases. Clin Oncol 2012;24:112–24.
13 Chow R, Hoskin P, Chan S, et al. Efficacy of multiple fraction conventional radiotherapy for painful uncomplicated bone metastases: a systematic review. Radiat Oncol 2017;12:233–31.
14 Rich SE, Chow R, Raman S, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiat Oncol 2018;126:547–57.
15 McQuay HJ, Collins SL, Carroll D, et al. Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev 2000;CD001793.
16 Mizumoto M, Harada H, Asakura H, et al. Prognostic factors and a scoring system for survival after radiotherapy for metastases to the spinal column: a review of 544 patients at Shizuoka cancer center Hospital. Cancer 2008;112:2816–22.
17 Caldwell DM, Ades AE, Higgins JPT. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897–900.
18 Salanti G, Marinho V, Higgins JPT. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol 2009;62:857–64.
Cipriani A, Higgins JPT, Geddes JR, et al. Conceptual and technical challenges in network meta-analysis. *Ann Intern Med* 2013;159:130–7.

Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.

Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015;162:777–84.

Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;339:b2535.

Atkins D, Eccles M, Flottorp S, et al. Checking consistency in mixed treatment comparison meta-analysis. *BMJ Open* 2010;29:932–44.

BMJ 2006;339:b1147.

Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. *Lancet Oncol* 2014;15:738–46.

Shahman RM, Meyers JE, Ut T, et al. Palliative radiation therapy (EBRT) for asymptomatic bone metastases in patients with solid tumors reduces the risk of skeletal-related events (SREs). *Ann Palliat Med* 2019;8:159–67.

Chow E, Wu JSY, Hoskin P, et al. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. *Radiother Oncol* 2000;64:275–80.

Zacher J, Kasenda B, Engert A, et al. The role of additional radiotherapy for primary central nervous system lymphoma. *Cochrane Database Syst Rev* 2014;CD009211.

Roos DE, Turner SL, O’Brien PC, et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman radiation Oncology group, TROG 96.05). *Radiother Oncol* 2005;75:54–63.

Ranzinger P, Altini D, Uhl A, et al. Palliative radiation therapy for musculoskeletal events in patients with advanced prostate cancer and bone metastases. *Radiother Oncol* 2014;137:1–8.

Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. *Lancet Oncol* 2014;15:738–46.

Shahman RM, Meyers JE, Ut T, et al. Palliative radiation therapy (EBRT) for asymptomatic bone metastases in patients with solid tumors reduces the risk of skeletal-related events (SREs). *Ann Palliat Med* 2019;8:159–67.

Chow E, Wu JSY, Hoskin P, et al. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. *Radiother Oncol* 2000;64:275–80.

Zacher J, Kasenda B, Engert A, et al. The role of additional radiotherapy for primary central nervous system lymphoma. *Cochrane Database Syst Rev* 2014;CD009211.

Roos DE, Turner SL, O’Brien PC, et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman radiation Oncology group, TROG 96.05). *Radiother Oncol* 2005;75:54–63.

Ranzinger P, Altini D, Uhl A, et al. Palliative radiation therapy for musculoskeletal events in patients with advanced prostate cancer and bone metastases. *Radiother Oncol* 2014;137:1–8.

Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. *Lancet Oncol* 2014;15:738–46.

Shahman RM, Meyers JE, Ut T, et al. Palliative radiation therapy (EBRT) for asymptomatic bone metastases in patients with solid tumors reduces the risk of skeletal-related events (SREs). *Ann Palliat Med* 2019;8:159–67.

Chow E, Wu JSY, Hoskin P, et al. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. *Radiother Oncol* 2000;64:275–80.

Zacher J, Kasenda B, Engert A, et al. The role of additional radiotherapy for primary central nervous system lymphoma. *Cochrane Database Syst Rev* 2014;CD009211.

Roos DE, Turner SL, O’Brien PC, et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman radiation Oncology group, TROG 96.05). *Radiother Oncol* 2005;75:54–63.

Ranzinger P, Altini D, Uhl A, et al. Palliative radiation therapy for musculoskeletal events in patients with advanced prostate cancer and bone metastases. *Radiother Oncol* 2014;137:1–8.

Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. *Lancet Oncol* 2014;15:738–46.

Shahman RM, Meyers JE, Ut T, et al. Palliative radiation therapy (EBRT) for asymptomatic bone metastases in patients with solid tumors reduces the risk of skeletal-related events (SREs). *Ann Palliat Med* 2019;8:159–67.

Chow E, Wu JSY, Hoskin P, et al. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. *Radiother Oncol* 2000;64:275–80.

Zacher J, Kasenda B, Engert A, et al. The role of additional radiotherapy for primary central nervous system lymphoma. *Cochrane Database Syst Rev* 2014;CD009211.

Roos DE, Turner SL, O’Brien PC, et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman radiation Oncology group, TROG 96.05). *Radiother Oncol* 2005;75:54–63.

Ranzinger P, Altini D, Uhl A, et al. Palliative radiation therapy for musculoskeletal events in patients with advanced prostate cancer and bone metastases. *Radiother Oncol* 2014;137:1–8.

Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. *Lancet Oncol* 2014;15:738–46.

Shahman RM, Meyers JE, Ut T, et al. Palliative radiation therapy (EBRT) for asymptomatic bone metastases in patients with solid tumors reduces the risk of skeletal-related events (SREs). *Ann Palliat Med* 2019;8:159–67.

Chow E, Wu JSY, Hoskin P, et al. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. *Radiother Oncol* 2000;64:275–80.

Zacher J, Kasenda B, Engert A, et al. The role of additional radiotherapy for primary central nervous system lymphoma. *Cochrane Database Syst Rev* 2014;CD009211.

Roos DE, Turner SL, O’Brien PC, et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman radiation Oncology group, TROG 96.05). *Radiother Oncol* 2005;75:54–63.

Ranzinger P, Altini D, Uhl A, et al. Palliative radiation therapy for musculoskeletal events in patients with advanced prostate cancer and bone metastases. *Radiother Oncol* 2014;137:1–8.